These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 2047690)

  • 41. In vitro effectiveness of povidone-iodine on Acanthamoeba isolates from human cornea.
    Gatti S; Cevini C; Bruno A; Penso G; Rama P; Scaglia M
    Antimicrob Agents Chemother; 1998 Sep; 42(9):2232-4. PubMed ID: 9736540
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tannic acid-modified silver nanoparticles as a novel therapeutic agent against Acanthamoeba.
    Padzik M; Hendiger EB; Chomicz L; Grodzik M; Szmidt M; Grobelny J; Lorenzo-Morales J
    Parasitol Res; 2018 Nov; 117(11):3519-3525. PubMed ID: 30112674
    [TBL] [Abstract][Full Text] [Related]  

  • 43. In vitro amoebicidal activity of propamidine and pentamidine isethionate against Acanthamoeba species and toxicity to corneal tissues.
    Alizadeh H; Silvany RE; Meyer DR; Dougherty JM; McCulley JP
    Cornea; 1997 Jan; 16(1):94-100. PubMed ID: 8985640
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Activity of the amidoamine myristamidopropyl dimethylamine against keratitis pathogens.
    Hughes R; Dart J; Kilvington S
    J Antimicrob Chemother; 2003 Jun; 51(6):1415-8. PubMed ID: 12716783
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of low concentrations of benzalkonium chloride on acanthamoebal survival and its potential impact on empirical therapy of infectious keratitis.
    Tu EY; Shoff ME; Gao W; Joslin CE
    JAMA Ophthalmol; 2013 May; 131(5):595-600. PubMed ID: 23519403
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Isolation and in vitro susceptibility of Acanthamoeba from a patient with keratitis.
    Lee GS; Hu FR; Tseng SH; Teng LJ; Ho SW; Luh KT
    Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi; 1989 Feb; 22(1):59-67. PubMed ID: 2791723
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Acanthamoeba keratitis successfully treated with prolonged propamidine isethionate and neomycin-polymyxin-gramicidin.
    John T; Lin J; Sahm DF
    Ann Ophthalmol; 1990 Jan; 22(1):20-3. PubMed ID: 1689978
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Bilateral Acanthamoeba keratitis in Synergeyes contact lens wear: clinical and confocal microscopy findings.
    Lee WB; Gotay A
    Eye Contact Lens; 2010 May; 36(3):164-9. PubMed ID: 20386314
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evaluation of the activity of new cationic carbosilane dendrimers on trophozoites and cysts of Acanthamoeba polyphaga.
    Heredero-Bermejo I; Copa-Patiño JL; Soliveri J; Fuentes-Paniagua E; de la Mata FJ; Gomez R; Perez-Serrano J
    Parasitol Res; 2015 Feb; 114(2):473-86. PubMed ID: 25358240
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Recommendations for the management of Acanthamoeba keratitis.
    Baig AM; Zuberi H; Khan NA
    J Med Microbiol; 2014 May; 63(Pt 5):770-771. PubMed ID: 24509420
    [No Abstract]   [Full Text] [Related]  

  • 51. Diagnosis and successful medical treatment of Acanthamoeba keratitis.
    D'Aversa G; Stern GA; Driebe WT
    Arch Ophthalmol; 1995 Sep; 113(9):1120-3. PubMed ID: 7661744
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Acanthamoeba keratitis--resistance to medical therapy.
    Ficker L; Seal D; Warhurst D; Wright P
    Eye (Lond); 1990; 4 ( Pt 6)():835-8. PubMed ID: 2101116
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A novel antiamoebic agent against Acanthamoeba sp.--A causative agent for eye keratitis infection.
    Kusrini E; Hashim F; Azmi WN; Amin NM; Estuningtyas A
    Spectrochim Acta A Mol Biomol Spectrosc; 2016 Jan; 153():714-21. PubMed ID: 26474244
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Acanthamoeba keratitis].
    Bouheraoua N; Labbé A; Chaumeil C; Liang Q; Laroche L; Borderie V
    J Fr Ophtalmol; 2014 Oct; 37(8):640-52. PubMed ID: 25169145
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Therapeutic agents and biocides for ocular infections by free-living amoebae of Acanthamoeba genus.
    Carrijo-Carvalho LC; Sant'ana VP; Foronda AS; de Freitas D; de Souza Carvalho FR
    Surv Ophthalmol; 2017; 62(2):203-218. PubMed ID: 27836717
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Acanthamoeba castellanii: A new high-throughput method for drug screening in vitro.
    Ortega-Rivas A; Padrón JM; Valladares B; Elsheikha HM
    Acta Trop; 2016 Dec; 164():95-99. PubMed ID: 27609636
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Acanthamoeba keratitis in a 5-year-old boy without a history of contact lens usage.
    Demirci G; Ay GM; Karabas LV; Altintas O; Tamer GS; Cağlar Y
    Cornea; 2006 Apr; 25(3):356-8. PubMed ID: 16633040
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Medical treatment for combined Fusarium and Acanthamoeba keratitis.
    Lin HC; Hsiao CH; Ma DH; Yeh LK; Tan HY; Lin MY; Huang SC
    Acta Ophthalmol; 2009 Mar; 87(2):199-203. PubMed ID: 18507727
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Good outcome in Acanthamoeba keratitis].
    Reichart-Peter S; Manousaridis K; Dirschmid H; Mennel S
    Ophthalmologe; 2017 Jul; 114(7):653-655. PubMed ID: 27558689
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A keratitis rat model for evaluation of anti-Acanthamoeba polyphaga agents.
    Vasseneix C; Gargala G; François A; Hellot MF; Duclos C; Muraine M; Benichou J; Ballet JJ; Brasseur G; Favennec L
    Cornea; 2006 Jun; 25(5):597-602. PubMed ID: 16783150
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.